Skip to content
value.today

MBX Biosciences, Inc.

🇺🇸 Carmel, Indiana, USAPharmaceuticalsFounded 2019
Total raised
$73 M
2 rounds on record
Latest round
$47 M
Nov 2022
First round on record
Jul 2020
Today
Went public
See the company page

MBX Biosciences, Inc. is listed today as MBX Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of MBX Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$47 MNo. 2$10 to $50 million

MBX Biosciences, Inc.: Raise no. 2, Nov 2022

Investors in this round

20 investors had bought by the notice of Nov 18, 2022: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for MBX Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$47 M of $115 M offered; $69 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter Kent Hawryluk · Executive Officer, Director
  • Richard Kent DiMarchi · Executive Officer, Director
  • Richard M. Bartram · Executive Officer
  • Carl M. Gordon · Director
  • Edward M. Mathers · Director
  • James M. Cornelius · Director
  • Ora Kent Pescovitz · Director
  • Patrick M. Heron · Director
  • Tiba M. Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold includes $10,184,444 from conversion of promissory notes”

Signed by Peter Kent Hawryluk, President & CEO. Source: SEC Form D, newest notice filed Nov 18, 2022. Read the notice at the SEC.

equitySEC
Jul 2020$26 MNo. 1$10 to $50 million

MBX Biosciences, Inc.: Raise no. 1, Jul 2020

Investors in this round

16 investors had bought by the notice of Jul 27, 2020: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for MBX Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $36 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter Kent Hawryluk · Executive Officer, Director
  • Richard Kent DiMarchi · Executive Officer, Director
  • Timothy Kent Knickerbocker · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Kent Hawryluk, President. Source: SEC Form D, newest notice filed Jul 27, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • MBX Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2022).

    SEC Form D · Nov 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2022

That is all the official record says: MBX Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of MBX Biosciences, Inc. are on record.

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in MBX Biosciences, Inc.
InvestorKindAmountRoundRoleSource
Fhmls X, L.L.C.Othernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Fhmls X, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Frazier Life Sciences X, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
James M. CorneliusPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2024)SEC Form 3
Nea 17 GP, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
NEA Partners 17, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
New Enterprise Associates 17, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3
OrbiMed Capital GP VII LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3
P. Kent HawrylukPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2024)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2024)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 20 investors.

Largest shareholders today

Institutions holding MBX Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by MBX Biosciences, Inc.
NameRoleNamed in
Peter Kent HawrylukExecutive officerNov 2022
Richard Kent DiMarchiExecutive officerNov 2022
Richard M. BartramExecutive officerNov 2022
Timothy Kent KnickerbockerExecutive officerJul 2020
Carl M. GordonDirectorNov 2022
Edward M. MathersDirectorNov 2022
James M. CorneliusDirectorNov 2022
Ora Kent PescovitzDirectorNov 2022
Patrick M. HeronDirectorNov 2022
Peter Kent HawrylukDirectorNov 2022
Richard Kent DiMarchiDirectorNov 2022
Tiba M. AynechiDirectorNov 2022
Timothy Kent KnickerbockerDirectorJul 2020

Went public since 2024. Its SEC number is that of a company listed on a stock exchange.